34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Modeling the ACMG/AMP Variant Classification Guidelines as a Bayesian Classification Framework

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          We evaluated the ACMG/AMP variant pathogenicity guidelines for internal consistency and compatibility with Bayesian statistical reasoning.

          Methods

          The ACMG/AMP criteria were translated into a naïve Bayesian classifier, assuming four levels of evidence and exponentially scaled odds of pathogenicity. We tested this framework with a range of prior probabilities and odds of pathogenicity.

          Results

          We modeled the ACMG/AMP guidelines using biologically plausible assumptions. Most ACMG/AMP combining criteria were compatible. One ACMG/AMP likely pathogenic combination was mathematically equivalent to pathogenic and one ACMG/AMP pathogenic combination was actually likely pathogenic. We modeled combinations that include evidence for and against pathogenicity, showing that our approach scored some combinations as pathogenic or likely pathogenic that ACMG/AMP would designate as VUS.

          Conclusion

          By transforming the ACMG/AMP guidelines into a Bayesian framework, we provide a mathematical foundation for what was a qualitative heuristic. Only two of the 18 existing ACMG/AMP evidence combinations were mathematically inconsistent with the overall framework. Mixed combinations of pathogenic and benign evidence could yield a likely pathogenic, likely benign, or VUS result. This quantitative framework validates the approach adopted by the ACMG/AMP, provides opportunities to further refine evidence categories and combining rules, and supports efforts to automate components of variant pathogenicity assessments.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

          Genetic testing of cancer susceptibility genes is now widely applied in clinical practice to predict risk of developing cancer. In general, sequence-based testing of germline DNA is used to determine whether an individual carries a change that is clearly likely to disrupt normal gene function. Genetic testing may detect changes that are clearly pathogenic, clearly neutral, or variants of unclear clinical significance. Such variants present a considerable challenge to the diagnostic laboratory and the receiving clinician in terms of interpretation and clear presentation of the implications of the result to the patient. There does not appear to be a consistent approach to interpreting and reporting the clinical significance of variants either among genes or among laboratories. The potential for confusion among clinicians and patients is considerable and misinterpretation may lead to inappropriate clinical consequences. In this article we review the current state of sequence-based genetic testing, describe other standardized reporting systems used in oncology, and propose a standardized classification system for application to sequence-based results for cancer predisposition genes. We suggest a system of five classes of variants based on the degree of likelihood of pathogenicity. Each class is associated with specific recommendations for clinical management of at-risk relatives that will depend on the syndrome. We propose that panels of experts on each cancer predisposition syndrome facilitate the classification scheme and designate appropriate surveillance and cancer management guidelines. The international adoption of a standardized reporting system should improve the clinical utility of sequence-based genetic tests to predict cancer risk. (c) 2008 Wiley-Liss, Inc.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.

            The clinical classification of hereditary sequence variants identified in disease-related genes directly affects clinical management of patients and their relatives. The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) undertook a collaborative effort to develop, test and apply a standardized classification scheme to constitutional variants in the Lynch syndrome-associated genes MLH1, MSH2, MSH6 and PMS2. Unpublished data submission was encouraged to assist in variant classification and was recognized through microattribution. The scheme was refined by multidisciplinary expert committee review of the clinical and functional data available for variants, applied to 2,360 sequence alterations, and disseminated online. Assessment using validated criteria altered classifications for 66% of 12,006 database entries. Clinical recommendations based on transparent evaluation are now possible for 1,370 variants that were not obviously protein truncating from nomenclature. This large-scale endeavor will facilitate the consistent management of families suspected to have Lynch syndrome and demonstrates the value of multidisciplinary collaboration in the curation and classification of variants in public locus-specific databases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

              Mutation screening of the breast and ovarian cancer-predisposition genes BRCA1 and BRCA2 is becoming an increasingly important part of clinical practice. Classification of rare nontruncating sequence variants in these genes is problematic, because it is not known whether these subtle changes alter function sufficiently to predispose cells to cancer development. Using data from the Myriad Genetic Laboratories database of nearly 70,000 full-sequence tests, we assessed the clinical significance of 1,433 sequence variants of unknown significance (VUSs) in the BRCA genes. Three independent measures were employed in the assessment: co-occurrence in trans of a VUS with known deleterious mutations; detailed analysis, by logistic regression, of personal and family history of cancer in VUS-carrying probands; and, in a subset of probands, an analysis of cosegregation with disease in pedigrees. For each of these factors, a likelihood ratio was computed under the hypothesis that the VUSs were equivalent to an "average" deleterious mutation, compared with neutral, with respect to risk. The likelihood ratios derived from each component were combined to provide an overall assessment for each VUS. A total of 133 VUSs had odds of at least 100 : 1 in favor of neutrality with respect to risk, whereas 43 had odds of at least 20 : 1 in favor of being deleterious. VUSs with evidence in favor of causality were those that were predicted to affect splicing, fell at positions that are highly conserved among BRCA orthologs, and were more likely to be located in specific domains of the proteins. In addition to their utility for improved genetics counseling of patients and their families, the global assessment reported here will be invaluable for validation of functional assays, structural models, and in silico analyses.
                Bookmark

                Author and article information

                Journal
                9815831
                22061
                Genet Med
                Genet. Med.
                Genetics in medicine : official journal of the American College of Medical Genetics
                1098-3600
                1530-0366
                18 January 2018
                04 January 2018
                September 2018
                17 January 2019
                : 20
                : 9
                : 1054-1060
                Affiliations
                [1 ]Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City UT
                [2 ]Department of Medicine and University of Vermont Cancer Center, University of Vermont Robert Larner, MD, College of Medicine, Burlington, VT
                [3 ]Partners HealthCare Laboratory for Molecular Medicine and Harvard Medical School, Boston, MA
                [4 ]Invitae, San Francisco, CA
                [5 ]Department of Genetics, Department of Biomedical Data Science, Stanford University, Palo Alto, CA
                [6 ]Department of Internal Medicine, Division of Epidemiology and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City UT
                [7 ]Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
                Author notes
                []Correspondence to: Sean V. Tavtigian, Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City UT 84112, USA. sean.tavtigian@ 123456hci.utah.edu
                [¥]

                The Clinical Genome Resource, Sequence Variant Interpretation Working Group:

                Antonis Antoniou, Cambridge University, Cambridge, UK

                Jonathan S. Berg, University of North Carolina, Chapel Hill, NC;

                Leslie G. Biesecker, National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD; Co-chair

                Steven E. Brenner, University of California, Berkeley, Berkeley, CA;

                Fergus Couch, Mayo Clinic, Rochester, MN;

                Garry Cutting, Department of Human Genetics, Johns Hopkins University School of Medicine. Baltimore, MD

                Marc S. Greenblatt, University of Vermont Robert Larner, MD, College of Medicine, Burlington, VT;

                Steven M. Harrison, Partners HealthCare Laboratory for Molecular Medicine and Harvard Medical School, Boston, MA; Co-chair

                Christopher D. Heinen, University of Connecticut Health, Farmington, CT;

                Matthew E. Hurles, Wellcome Trust Sanger Institute, Hinxton, UK;

                H. Peter Kang, Counsyl, San Francisco, CA;

                Rachel Karchin, Johns Hopkins University School of Medicine, Baltimore, MD;

                Robert L. Nussbaum, Invitae, San Francisco, CA;

                Sharon E. Plon, Baylor College of Medicine, Houston, TX;

                Heidi L. Rehm, Partners HealthCare Laboratory for Molecular Medicine and Harvard Medical School, Boston, MA

                Sean V. Tavtigian, Department of Oncological Science and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT

                Article
                NIHMS915467
                10.1038/gim.2017.210
                6336098
                29300386
                16e327b0-4b00-44b7-ad74-02065417c3a4

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Genetics
                Genetics

                Comments

                Comment on this article

                scite_

                Similar content175

                Cited by178

                Most referenced authors173